Index

All headings refer to ibuprofen except where otherwise stated. Other common NSAIDs are listed in index, for less common NSAIDs. see comparative studies

Locators in italic refer to figures and tables (not shown where they fall on same pages as general subject matter)

A metabolites, medicinal chemistry 36–8
Abbott Laboratories Inc. 19
abdominal adhesions 203–4
abdominal writhing test 143, 240
absorption 53
elderly patients 330
fast-acting preparations 65, 111
in vitro/in vivo testing 59–60
pharmacokinetics 82–3
rheumatic diseases 246
toxic effects relative to plasma concentration 107–8
ACE (angiotensin-converting enzyme) inhibitors 484
acetylcholine-induced mouse writhing test 143, 240
acidity, gastric 396, 397–9, 402–4
acrylic acid 37, 41
acute anti-inflammatory effects, pharmacology 136–41.
see also inflammation
acute lung injury 198–9
acute myocardial injury 199–201
acute pain, pharmacokinetics 108–14
acyl co-enzyme A 240
acyl glucuronidated ibuprofen 93, 104, 133, 436, 437
Adams, Dr Stewart 25
history 2, 3, 5–7, 9, 11, 15–16, 22–3
laboratory 4, 5
adhesion, cellular 184–5
adhesions, abdominal 203–4
Adiro (R). see dexibuprofen
adjuvant arthritis 141–3, 143, see also animal models
adult respiratory distress syndrome (ARDS) 83, 196–8
adverse drug reactions (ADRs) 452–3, 487, 315, 316, 317
allergic/hypersensitive 254, 453–7
chronic use 513–14
comparative studies 275–6
drug interactions 482–6
endocrine 480
future research needs 486–7
haematological 465–6, 512
history and development 5, 6, 11, 12, 14, 22, 25
ibuprofen analogues 32, 33, 34
immunological 210–11, 253, 254
musculoskeletal 323
necrotizing fasciitis 191, 482
respiratory 323, 512
rheumatic patients 248–54
see also cardiovascular; central nervous system;
dermatological; gastrointestinal; hepatic; ocular;
renal; and reproductive effects; safety; toxicology
age factors
PAIN study 321, 322
pharmacokinetics 84, 86
see also elderly patients; pediatrics
agranulocytosis 5, 6, 465–6
Albermarle drug company 51–2
albumin binding 330, 479, 558
gastrointestinal effects 408
pharmacokinetics 83, 88, 89, 119, 277
rheumatic diseases 246–7
alcohol-induced teratogenic activity 254
alcohol use 396, 437, 440, 509–10
allergy 453–7, see also hypersensitivity
alminoprofen 34
aluminium hydroxide, taste-masking 69
Alzheimer’s disease 254, 549, 550, 559
cellular/molecular effects of NSAIDs 555–9
clinical trials 551–5
pathogenesis 550–1
American College of Rheumatology (ACR)
guidelines 264
amidopyrine, history 3
aminoglycosides, drug interactions 485
aminophenols (phenacetin), history 5
analgesia 133
chronic pain 245–7, 281–5, 287
dentistry 111, 347–55
experimentally induced pain 205–6
pain pathways 145
pharmacology/toxicology 134, 135, 143–9
pharmokinetics 108–14
rheumatic diseases 245–7, 258, 271
anaemia 466
analgesics of ibuprofen 31–5
angiotensin-converting enzyme (ACE) inhibitors 484
animal models
Alzheimer’s disease 556–8
analgesia 143–9
cancer prevention/therapy 523, 524–5
cerebral injury 201–2
comparative ulcerogenicity 150–3
compounds in development 12, 25, 26
coronary function 199–201
endotoxinemia 196–8
history 2
inflammation 134–6, 138–9, 140, 141–3
pharmokinetics of ibuprofen 83, 94, 105–6
pregnancy 331
reproductive toxicity 477–8
ankylosing spondylitis 280
antacids 120–1, 379, 410–12, 438. see also proton pump inhibitors
anthraquinone-functionalized alcohol 35
anti-epileptic drug interactions 123
antibiotics, hepatic reactions 438
anti-coagulants, drug interactions 484–5. see also warfarin
anti-erythema effects, flurbiprofen 136
anti-hyperlipidemic drugs, drug interactions 121–2
anti-hypertensive therapy, drug interactions 483
anti-inflammatory effects. see inflammation
anti-ischemic effects 202
anti-oxidant effects 43. see also reactive oxygen species
anti-pyretic effects 133
compounds in development 22–3, 24
pharmacology/toxicology 135, 149
rheumatic diseases 240
anti-thrombotic effects 133, 330
anti-ulcer medications, drug interactions 120–1. see also antacids; proton pump inhibitors
aplastic anaemia 465–6
arachidonic acid metabolism 166–8, 169, 172
ARDS (adult respiratory distress syndrome) 83, 196–8
area under drug concentration curve (AUC) 82–9, 91, 92
chiral inversion 101, 102
versus dose 92, 93
drug interactions 122–3
pain sufferers 110, 113
arginine 64, 147–8
arthritis
chronic anti-inflammatory effects 141–3
haemophilic arthritis 281
pharmokinetics of ibuprofen 84, 86
psoriatic arthritis 280
reactive arthritis 280
Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS) 367–8
Arthritis and Rheumatism Council, history 3
arylpropionic acids, synthetic routes to ibuprofen 29
aseptic meningitis 481
aspartase aminotransferase (AST) 459
aspirin
adverse drug reactions 6, 317, 374
allergy/hypersensitivity 455
anti-arthritic effects 142
cancer prevention/therapy 520, 527–8, 531–2
cardiovascular effects 330
clinical trials 12–14
combination therapy 330
comparative studies 137, 139, 140, 142, 143, 144, 145–9
Cr-labelled red blood cell technique 391
drug interactions 123, 486
gastrointestinal effects 151, 249, 364, 372, 374, 382, 386, 400–2
hepatic toxicity 435, 438, 440
history 2–3, 5, 6, 10, 15, 22–3
PAIN study 317–23
pharmacology/toxicology 133, 156, 174, 176
pregnancy 332
asthenia (weakness) 320
astrocytes, Alzheimer’s disease 554, 556, 557, 558, 559
ASTRONAUT healing study 411–12
AUC. see area under drug concentration curve
autoimmune hemolytic anaemia 466
‘B’ metabolites, medicinal chemistry 36–8
back pain 278–9, 320
baclofen, drug interactions 123
barbiturates, drug interactions 123
beadlet formulations 63
behavioural disturbance 285
benoxaprofen, hepatic toxicity 434, 435
benzylamine 40
beta-blockers, drug interactions 484
beta-endorphins 206, 347, 356, 357
beta-synuclein 561
bioavailability 57, 58–9, 82, 83
biotransformation reactions 94. see also clearance
bleeding/blood loss 246, 316
clinical trials 326
Cr-labelled red blood cell technique 389–94
epidemiological data 329
gastrointestinal 208–10, 248, 249, 250, 363–9
blister fluid 89–90, 242–3
blood disorders, adverse drug reactions 465–6, 512
blood loss. see bleeding/blood loss
bone destruction, osteoarthritis 272–3
Boots–Hoechst–Celanese process 31
Boots Pure Drug Company Ltd, Bishop, Texas, USA 51
Boots Pure Drug Company Ltd, Nottingham, UK 51
biological activity of ibuprofen analogues 31, 33
history 2, 3, 6, 10, 15, 17–19, 22–3
synthetic routes to ibuprofen 27–31
brands 579–82. see also formulations
breakdown products, marker 51
breast cancer prevention 520, 521, 523–5, 528–9, 532
breast milk, distribution 91. see also lactation
Brufen™, history 15, 19, 25, 573–6
BTS 7268 10, 11
BTS 8402 10, 11, 23–4
BTS 10335 11, 15, 24, 25, 238
BTS 10499 11, 12, 15, 24, 25
BTS 11654 24, 25
Buckler, Dr J. Warwick 17
bulk, product 65, 66
burn patients 119
burning sensation on swallowing 50, 53, 62, 67
Burrows, Colin 3, 4, 7, 16
Busson, Dr Mervyn 17, 18
C-labelling, 2-arylpropionic acids 31
'C' metabolites, medicinal chemistry 36–8
caffeine formulations 354
Canada 460, 462
cancer prevention/therapy 1, 163, 284, 520–1
animal studies 523, 524–5
biological actions of ibuprofen 212–13
COX-1/COX-2 inhibition 522–3, 524, 533–7
epidemiological data 525–31
future research needs 536–7
preclinical efficacy studies 523–4
safety issues 535–6
therapeutic studies 531–2
carboxyibuprofen 36, 94, 105
carboxylic acids 23
biological activity 32
comparative ulcerogenicity 160
history 10
metabolites of ibuprofen 37, 94
cardiovascular effects 199–201, 239, 251, 252, 253, 470–7
biological activity of ibuprofen analogues 35
cancer prevention/therapy 536
clinical trials 323
elderly patients 285
epidemiological data 330
toxicity 511
carrageenan oedema 10, 32, 136, 138–9, 140
Carter, David 17–18
cartilage 192–4, 262–3, 272–3
catalysed carboxylation 29
cataracts 213–14, 254
celecoxib
pharmacology/toxicology 155, 172, 174
rheumatic disorders 238, 250–3, 274, 275, 276
cellular effects of NSAIDs
Alzheimer’s disease 555–9
leukocyte interaction 184–5
central nervous system effects 253, 316, 480–1
analgesia 145, 147
elderly patients 325
headache 285, 320, 480–1
overdosage 511
psychiatric effects 285, 481
cerebral injury 201–2
cerebrospinal fluid, tissue distribution 91
CGHG (Clinician Global Impression Change) 247
Chalmers, Dr Tom 12–14, 17
chemical specifications, ibuprofen 52, 53
chemical structure, ibuprofen 11, 51
chemotaxis, lymphocyte 184–5
chewable tablets, taste-masking 69
children. see pediatrics
Chinese, ethnic differences in side-effects 244–5
chiral inversion 38–42, 409
analgesia 111
anatomical site 99–104
 mechanism 97–9
non-stereospecific analysis 96–7
pharmokinetics 81, 82, 92, 94–104
chloroform, solubility of ibuprofen in 53
cholestyramine, drug interactions 121–2
chronic anti-inflammatory effects 141–3. see also inflammation
chronic pain 245–7, 281–5, 287. see also analgesia
chronic use, toxicity 513–14
cimetidine, drug interactions 120, 203
cinchophen, hepatic toxicity 433–4, 435
cirrhosis 84–5, 111, 433–4. see also hepatic effects
Class 2 drug, Pharmaceutical Drug Classification 50, 64
CLASS study 376–8, 388, 412
clearance, pharmokinetics 92–105, 133, 243, 315
Clinical Disease Activity Index (CDAI). 255
clinical pharmacology 204–14, 239–47
clinical potency. see potency
clinical trials 12–14
Alzheimer’s disease 551–5
gastrointestinal effects 376–8
PAIN study 317–23
renal effects 467
safety and effectiveness 315–27
Clinical Global Impression Change (CGIG) 247
clofibric acid, drug interactions 122, 438
clonidine 283
CNS. see central nervous system
coating materials 60, 61, 62, 63, 68–9
Cobb, Ray 16
Cochrane Database Systematic Review
Alzheimer’s disease 552
febrile children and infants 445
codeine
combination drugs 329–30, 351–2, 354, 359
drug interactions 121
cognitive dysfunction 285, 481
cohort studies, cardiovascular effects 475–6
colestipol, drug interactions 121–2
colon cancer prevention/therapy 520, 521, 525–9, 532
combination drugs 580–2
analgesia 350–4, 358–9
epidemiological data 329–30
fast-acting preparations 64
gastrointestinal effects 411
Committee on the Safety of Medicines (CSM) 17
compaction properties of ibuprofen 56, 56–7, 62, 65, 66
comparative studies
adverse drug reactions 208, 317–27
cancer prevention/therapy 526–8
cardiovascular effects 252, 253
cataract 213
Cr-labelled red blood cell technique 389–94
cyclooxygenase inhibition 173–80
enteropathy 381–9
epidemiological data 327–30
gastrointestinal effects 250, 363–4, 369–78, 381, 399–402
hepatic effects 253
osteoarthritis 265–70, 274–6
pharmacological 150–3, 156–8
potency 137, 139, 140, 142, 143, 144, 145–9, 180
pregnancy 332–3
prostaglandins production 165, 166–8
rheumatic diseases 237–9, 259–60
toxicity and overdose 516
see also specific NSAIDs by name
concurrent drug intake. see drug interactions
conditional pharmacology/toxicology 432–3
conformational analysis, physiochemical
properties 42–3
coronary function 199–201. see also cardiovascular
effects
corticosteroids, history 5, 10
cortisone, history 2–3, 6
cost, fast-acting preparations 65
COSTART (Coding Symbol Thesaurus for Adverse Reaction Terms) classification 319, 320, 323
COX. see cyclooxygenase
coxibs (cyclooxygenase-2 inhibitors) 237–9
adverse drug reactions/toxicity 250, 251, 252, 374
cancer prevention/therapy 520, 521, 524, 527–8
cardiometabolic side-effects 252, 471
comparative studies 274–6
Cr-labelled red blood cell technique 393
gastrointestinal effects 253, 369–74
hepatic toxicity 253, 438, 465
renal effects 442, 445
see also celecoxib; rofecoxib
C-reactive protein (CRP) 255
Cr-labelled red blood cell technique 389–94, 406
crystal form 57
CSM (Committee on the Safety of Medicines) 17
cystic fibrosis 116, 212
cytochrome system 94, 133, 435
cytokines. see pro-inflammatory cytokines
‘D’ metabolites, medicinal chemistry 36–8
Darzens glycidic ester synthesis 29
delayed-onset muscle soreness (DOMS) 315, 334–5
delayed-type hypersensitivity reactions (DTH) 203.
  see also hypersensitivity
dementia 1, 254. see also Alzheimer’s disease
dentistry 346–7
  analgesia 111, 347–55
  beta-endorphins 347, 356
  combination drugs 350–4, 358–9
  oedema-reducing effect 355–6
  pharmokinetics of ibuprofen 88
  recommendations for use of ibuprofen 358–9
  temporomandibular pain 356–8
  therapeutic effects relative to plasma concentration 107
Department of Health and Social Security (DHSS), UK 17, 18
dermatological effects 238, 457–8, 459, 512–13
  clinical trials 14, 323
  history and development 11, 14, 25
  development. see history and development
dexibuprofen 39, 66, 270, 278, 286, 580. see also S–ibuprofen
diabetic neuropathy 283
diclofenac
  adverse drug reactions/safety 135, 326, 374, 465
  animal studies 139
  anti-arthritic effects 142
  anti-erythema activity 136
  cardiovascular risk 252
  gastrointestinal effects 151, 155, 249, 250, 253, 325, 370, 375, 377, 382, 386
  hepatic toxicity 434, 435, 436, 437, 441
  pharmacology 132, 156, 165, 166, 173, 174, 176, 178, 180
  pharmokinetics 121
  rheumatic diseases 275
diflunisal 5, 166, 372, 375. see also comparative studies
dimethyl sulfoxide 53
Disease Activity Score with 28-joint counts 255
disease-modifying anti-arthritic drugs (DMARDs) 142
  adjuvant arthritis 142
  hepatic toxicity 440
  rheumatoid arthritis 255
dissolution testing 58–60
distribution, pharmokinetics of ibuprofen 83–92, 243
diuretics, drug interactions 484
dizziness 285, 315, 320, 406, 480–1, 511
DLIs (drug-induced liver injuries) 437. see also hepatic effects
dogs
  comparative ulcerogenicity 150–3
  compounds in development 12, 25, 26
  pharmokinetics of ibuprofen 105
  see also animal models
DOMS (delayed-onset muscle soreness) 315, 334–5
dosage 82
  allergy/hypersensitivity 454
  osteoarthritis 264
  rheumatic diseases 239, 241, 255–62
  and toxicity 502–8. see also overdosage
  versus area under drug concentration curve 92, 93
  drowsiness 285
drug interactions
  adverse drug reactions 482–6
  gastrointestinal effects 395
  hepatic toxicity 439–41
  pharmokinetics of ibuprofen 120–3
  drug-induced liver injuries (DLIs) 437. see also hepatic effects
  drug reactions. see adverse drug reactions
ductus arteriosus, constriction 253
Duthie, Dr Ian 6, 17
dyspepsia 248
Dytransin 25. see also ibufenac
ear lobe stimulated nociception 243
effervescent formulations 54, 58, 59, 60, 64, 66, 111, 112
eicosanoids 169–70. see also prostaglandins
EIMD (exercise-induced muscle damage) 334–5
elderly patients 285
  central nervous system toxicity 481
  gastrointestinal effects 395
  pharmokinetics of ibuprofen 84, 86, 117
  safety and effectiveness 324, 325, 330–1
  elimination of ibuprofen 53, 246
Empire Rheumatism Council (Arthritis and Rheumatism Council), history 3
enantiomers of ibuprofen 349–50
  analgesia 349–50
  enantiomer-enantiomer interactions 123
  inversion 36–7, 240
  medicinal chemistry 38–42
  see also chiral inversion; R–ibuprofen; S–ibuprofen
  endocrine system effects 480
  endorphins 206, 347, 356, 357
  endoscopy
    enteropathy, NSAID 381–9
    gastrointestinal assessment 380–1, 399–402
    endothelial cells, leukocyte interaction 184, 185, 186–8
endothelium-dependent relaxation factor (EDRF) 200–1
endotoxinemia 196–8
energy metabolism 334
enteric coatings 60, 61, 62, 63
enteropathy, NSAID 364, 365, 381–9
environmental factors, rheumatoid arthritis 254–5
epidemiological data
  adverse drug reactions 487
  allergy/hypersensitivity 454–7
  cancer prevention/therapy 525–31
  gastrointestinal effects 248–50, 369–76
  hepatic toxicity 459, 461–4
  renal effects 468–70
  safety and effectiveness 327–30
  toxicity 501–2
  see also mortality/morbidity
erythrocyte sedimentation rate (ESR) 255, 257
estomer formulations
  compounds in development 10
  medicinal chemistry 23, 27, 29–32, 35, 36, 38, 40, 42
  pharmaceutics of ibuprofen 61, 62, 68, 70, 71
  pharmokinetics of ibuprofen 82
  ethanol, solubility of ibuprofen 53
ethnic differences 119–20, 244–5
  rheumatoid arthritis 256–7
side-effects 12, 15, 25, 244–5, 434
etodolac
  gastrointestinal effects 372, 382, 400, 401
  pharmacology 174, 176
etoricoxib, 239, 252. see also comparative studies
European League Against Rheumatism (EULAR) 264
European Pharmacopoeia 52, 58
excretion 104–5, 331
exercise-induced muscle damage (EIMD) 334–5
experimental therapeutics, pharmacology 196–204
experimentally-induced pain/inflammation 204–6
eyes. see ocular effects
febrile states 262, 286
  children and infants 86, 114–15, 247. see also pediatrics
  primary and secondary osteoarthritis 271
  fibrinolytic properties, ibuprofen analogues 35
  fibromyalgia 281
  finger joint osteoarthritis 264
  5-aminosalicylic acid-ibuprofen amide conjugate 160
  5-hydroxy-tryptamine (5-HT), effect on gastric acidity 404
  flatulent dyspepsia 14
  flufenamic acid
    anti-erythema activity 136
    gastrointestinal effects 151
    hepatic toxicity 436
    history 3
flurbiprofen 92–3
  adverse drug reactions 461, 477, 483, 484, 485
dentistry 355
  gastrointestinal effects 142, 152, 372, 382, 386, 400–2
  history and development 16
  medicinal chemistry 31
  neurodegenerative disorders 556, 558, 559
  pharmaceutics 70
  pharmokinetics 92, 93, 94, 106, 107, 123
  rheumatic diseases 264, 275, 280
food, absorption effects 82, 380, 406–9
Food and Drug Administration (FDA), US 18
formulations 579–82
dentistry 354–5
  fast-acting preparations 64–6
  gastrointestinal effects 404–6
  liquid preparations 67, 245, 261–2
  rheumatic diseases 276
  solid dosage form 53, 54–66
  suppositories 69, 82–3
taste-masking 67–9
  topical 70–2, 276, 390–402
  see also effervescent formulations; pharmaceutics; sustained release technologies
formyl-methiomyl-leucyl peptide (fMLP) 184
4-biphenyl compound, history 23, 24
4-bromophenyl, synthetic routes to ibuprofen 30
4-isobutylacetophenone 28–9, 31
4-isobutylbenzene, synthetic routes to ibuprofen 31
4-isobutylphenol, synthetic routes to ibuprofen 30
4-isobutyrylacetophenone (IBAP) 51
4-phenylproponic acids, history 12
freeze-dried matrix, taste-masking 69
Index

Friedel–Crafts acylation 31
frostbite 285
gastric acidity 396, 397–9, 402–4
gastric motility, pain sufferers 111
gastrointestinal chiral inversion 99–104
gastrointestinal effects 132, 239, 314, 315, 316, 363–5
assessment procedures 379–95
cancer prevention/therapy 535
clinical trials 323, 376–8
comparative studies 150–3, 378
elderly patients 285, 324, 325
enantiomers of ibuprofen 39
epidemiological data 328–9, 369–76
factors affecting 395–9
and gastric acidity 396, 397–9, 402–4
and H. pylori 275, 363, 367, 388, 395, 402, 410, 412
history and development 6, 10, 25
ibuprofen analogues 32, 33, 35
mechanism 153–61
mitigation strategies 404–12
PAIN study 320, 321, 322
pharmacology 133, 208–10
physiochemical properties affecting 399–402
primary and secondary osteoarthritis 264
rheumatic diseases, chronic pain 248–51
safety assessment 14–15, 18, 412
symptom-based studies 378–9
toxicology 149–61, 508
ulceration with bleeding. see gastrointestinal haemorrhage
gastrointestinal haemorrhage 208–10, 248, 249, 250, 363, 364, 365–9
gastrostomosis 333
gender
- gastrointestinal effects 248, 250
- PAIN study 321
- pharmacokinetics of ibuprofen 86, 119–20, 243–4
General Practice Database (UK) 371
General Practice (GP), PAIN study 317–23
general sales outside pharmacies (GSL) status 17
genetics
- adverse drug reactions/safety 331, 396, 437
- clearance 94
- glucuronidated ibuprofen 93, 104, 133, 436, 437
- glucuronide ester metabolites of ibuprofen 36
- gold salts, history 5
- golden era of Edisonian empiricism 5
- Good Clinical Practice (GCP) guidelines, clinical trials 376
gout 280–1
GRADE Workshop (2000) definitions of safety 315
- granulation process, tablets 56–8
- GREETs (Group for the Respect of Ethics and Excellence in Science) 247
- GSL (general sales outside pharmacies) status 17
- guidelines
- clinical trials 376
- primary and secondary osteoarthritis 264
guinea pig studies
- acute anti-inflammatory effects 136–7
- chiral inversion 102
- pharmacokinetics of ibuprofen 106
topical presentations 71
- see also animal models; UV erythema assay
gut microflora 153, 156–8, 255, 363
gynaecological conditions 211–12. see also reproductive effects
- haematological effects 465–6, 512
- haemoglobin assay 394–5
- haemolytic anaemia 253
- haemophiliac arthritis 281
- haemorrhage. see bleeding/blood loss
- half-life 60
- headaches 285, 320, 480–1
- heart function 199–201. see also cardiovascular effects
- heartburn 316. see also gastrointestinal effects
- Helicobacter pylori 275, 363, 367, 388, 395, 402, 410, 412, 508
- hepatic effects 133, 251, 253, 432–9, 446
- adverse drug reactions 458–65
- coxibs 238
- drug interactions 439–41
- epidemiological data 459, 461–4
- history 433–4
- ibufenac 12, 15, 25
- and osteoarthritis 264
- pharmacokinetics of ibuprofen 119
- risk factors 437, 440
- toxicology 161–3
- hepatocellular chiral inversion 104
- herbal medications 86, 438, 440
- herpes genitalis 284
- hexane, solubility of ibuprofen 52
- hip arthroplasty 285
- histamine H2-receptor antagonists, drug interactions 120–1
- history and development 12–17
- background 1–10, 22–3
- compounds in development 10–12, 15, 23–5
- hepatic toxicity 433–4
- over-the-counter status 17–19
- worldwide developments 19
- Hobday, Gordon 22
hydrocodone, combination drugs 55, 354, 359, 580
hydroxyibuprofen, urinary excretion 105
hydroxylation, clearance pathways 94
hydroxypropylmethylcellulose (HPMC) 61
hypersensitivity reactions 203, 210–11, 254, 453–7
hypoglycemic drugs, drug interactions 485
iatrogenic ileo-caecitis (enteropathy) 364, 365, 381–9
IBAP (4-isobutyrylacetophenone) 51
ibufenac 28, 30
chemical structure 11
hepatic toxicity 434, 435, 436
history 12, 15, 25
rheumatic diseases, chronic pain 238
ibuprofen. see all entries in index (except where otherwise stated)
ibuprofen esters 35
ibuprofen lysinate 64–5
ibuprofen sodium dihydrate 66
ibuproxam, biological activity 32
ileo-caecitis, iatrogenic (enteropathy) 364, 365, 381–9
Imbrun (ibuprofen lysinate) 64–5
immune function
pharmacology/toxicology 133, 136–41, 432–3
primary and secondary osteoarthritis 271
principal modes of action 135
rheumatoid arthritis 245–7, 254–5, 257–8
see also oedema-reduction; pro-inflammatory cytokines
Institute of Medicine (IOM) 315
interleukins (ILs) 190–1
anti-pyretic effects 149
pharmacology/toxicology 138
primary and secondary osteoarthritis 262
rheumatoid arthritis 255
interspecific studies. see animal models
intestinal microbial flora 153, 156–8, 255, 363
intrathecal ibuprofen, potency 147
inversion, enantiomer 36–7
iridocyclitis 204
iron status, arthritic diseases 142
ischemia/anti-ischemic activity of ibuprofen 202
isobutylbenzene, synthetic routes to ibuprofen 30, 31
isomers of ibuprofen 349–50. see also enantiomers
Italy 55, 463
J. R Geigy, Switzerland, history 3
Japan 12, 15, 25, 256–7, 434
joint flexion of rats, adjuvant arthritis 143
joint integrity, pharmacology/toxicology 192–4
juvenile (idiopathic) rheumatoid arthritis (JRA) 116, 261–2
ketoprofen
adverse drug reactions 317, 374
anti-arthritic effects 142
anti-erythema activity 136
biological activity 33
gastrointestinal effects 151, 249, 370, 372, 375, 382, 386, 400, 401, 402
pharmacology 156, 165, 166, 174, 176
kidney. see renal effects
kinin antagonism 10
knee pain, clinical trials 327
knock-out mice, genetic studies 331
lactation
breast milk distribution 91
safety and effectiveness 331–3
toxicity and overdose 513
layered double hydroxides (LDHs) 57
Lessel, Dr Barrie 12
leucocyte inhibition 132, 139, 182–91, 255
leukotrienes 132, 180–1
Lewis, Colin 17
lipid metabolism, pharmacology/toxicology 194–5
lipid-lowering drugs, drug-induced liver injuries 438
liquid preparations 67, 245, 261–2
lithium, drug interactions 123, 485
liver toxicity. see hepatic effects
long-term storage properties 43
low back pain 278–9
low density lipoprotein (LDL) binding 42–3. see also lipid metabolism
lung cancer prevention/therapy 520, 521, 532
epidemiological data 525, 526, 527, 528, 530–1
lung inflammation, cystic fibrosis 212
lung injury 198–9
lung and respiratory effects 323, 512
lymphocyte chemotaxis 184–5
lysine salts 64–5, 152, 354, 404–6, 580
major histocompatibility complex (MHC) 255
males. see gender
malignancy. see cancer prevention/therapy
MAPKs (mitogen-activated protein kinases) 263
markers, chemical breakdown products 51
matrix pellets 63
maximal-use, safety and tolerance (MUST) 315
MCID (minimal clinically important difference) 247
McNeil Consumer Healthcare 19
MCP-1 (monocyte chemotactic protein-1) 255
meals, absorption effects 82, 380, 406–9
MEDAL study, gastrointestinal effects 377
Medical Research Council, history 3
medicinal chemistry
biological activity of ibuprofen analogues 31–5
compounds in development 22–6
enantiomers of ibuprofen 38–42
metabolites of ibuprofen 36–8
physiochemical properties 42–3
synthetic routes to ibuprofen 27–31
Medicines Monitoring Unit (MEMO), Tayside (Scotland) 368
mefenamic acid
anti-erythema activity 136
gastrointestinal effects 151, 370
hepatic toxicity 436
history 3, 10
pharmacology 156, 166, 174, 176
melting point 57
meningitis 254, 481
Merck and Company, USA, history 3, 5
meta-analyses
 cancer prevention/therapy 528, 530–1
gastrointestinal haemorrhage 249
metabolic effects, toxicity 510–11
metabolism of ibuprofen 93–104, 133, 330–1
metabolites of ibuprofen, medicinal chemistry 35, 36–8
methotrexate, drug interactions 485
methylation, acid side chain synthetic routes to ibuprofen 27
MHC (major histocompatibility complex) 255
microcapsules, taste-masking 68
microfluidic separation technique 40
microglia, Alzheimer’s disease 555, 556, 557, 558, 559
microspheres/microparticles 63
microvasculature 182–3
military missions, pharmokinetics of ibuprofen 120
milk, tissue distribution 91. see also lactation
minimal clinically important difference (MCID) 247
minimatrices 63
misoprostol, drug interactions 121
mitogen-activated protein kinases (MAPKs) 263
molecular effects of NSAIDs, Alzheimer’s disease 555–9
monocyte chemotactic protein-1 (MCP-1) 255
mortality/morbidity
gastric ulceration associated with bleeding 365, 366–9
overdosage 502, 503–4, 512
Morton, Dr Eric V. B., history 17
Motrin 14, 19, 579
mucosa, gastric 409–10. see also gastrointestinal effects
MUCOSA study, gastrointestinal effects 376–8, 388
multisystem organ failure, chronic use 514
muscle tissue distribution 92
musculoskeletal conditions 237, 239. see also rheumatic diseases
musculoskeletal effects, clinical trials 323
MUST (maximal-use, safety and tolerance) 323
Mycobacterium tuberculosis 141–3
myeloperoxidase activity 188–90
myocardial injury 199–201. see also cardiovascular effects
naproxen 262, 275
adverse drug reactions 317, 374
allergy/hypersensitivity 456
anti-arhritic effects 142
anti-erythema activity 136
cardiovascular risk 252
epidemiological data 329
gastrointestinal effects 151, 249, 250, 253, 370, 375, 382, 386, 400–2
pharmacology 156, 165, 166, 174, 176
rheumatic diseases 275
National Poisons Information Service 515
nausea 316, 320, 323
necrotizing fasciitis 191, 482
nerve root compression patients 84
nervous system. see central nervous system; peripheral nervous system
Netherlands 456–7
neurodegenerative disorders 549–50, 561–2
  Alzheimer’s disease 254, 549–59
  biological activity of ibuprofen analogues 35
  Parkinson’s disease 1, 559–61, 562
  Nurofen Plus (ibuprofen with codeine), epidemiological data 329–30
neutropenia 465–6
N-glucuronide, clearance pathways 94
Nicholson, John 2, 3, 4, 9, 10, 11, 16, 17, 23, 24
nimesulide
  gastrointestinal effects 382, 400, 401, 402
  pharmacology 174
nitric oxide (NO) 132, 147–8
  coronary function 200–1
  pharmacology 181–2
N-methyl-D-aspartate (NMDA) receptors 146
N-methyl-D-glucamine 40
non-stereospecific analysis, chiral inversion metabolic pathways 96–7
Northern General Hospital, Edinburgh 12–14, 17
NSAID enteropathy 381–9
Nurofen™ (trade mark brand of ibuprofen) 18, 406

OARSI. see OsteoArthritis Research Society International
obstetrics 211–12. see also reproductive effects
octanol, solubility of ibuprofen 53
octreotide, comparative ulcerogenicity 160
ocular effects 204, 254, 481–2
  cataract 213–14, 254
oedema-reduction 23, 182–3, 355–6. see also inflammation/anti-inflammatory effects of ibuprofen; carrageenan oedema
olefins, catalysed carboxylation 29
oligohydramnios, adverse drug reactions 479
oliguria 253
omeprazole 411–12
OMERACT (Outcome Measures in Rheumatology Group) 247
oral contraceptives, drug interactions 122–3
oral suspensions 67, 245, 261–2
  organ failure, chronic use 514
organoboranes, synthetic routes to ibuprofen 30
osteoarthritis 237
  pharmokinetics of ibuprofen 86, 241, 242
  primary and secondary 262–76
  safety 315
  sustained release technologies 62
  see also rheumatic diseases
  Osteoarthritis Research Society International (OARSI) 247, 264
overdosage 133, 500–1
  cardiovascular effects 511
  central nervous system toxicity 511
  chronic use 513–14
  dermatological effects 512–13
  dose-response 502–8
  epidemiological data 501–2
  gastrointestinal effects 508
  haematological effects 512
  management of patients 514–16
  metabolic effects 510–11
  pregnancy/breast-feeding 513
  renal effects 509–10
  respiratory effects 512
  see also adverse drug reactions; safety; toxicology
over-the-counter (OTC) status 1, 17–19, 245, 313–14, 500
oxidative metabolism 94
oxycodone
  combination drugs for analgesia 352–3
  drug interactions 121
oxygen radicals 132, 188–90, 334, 561

pain, experimentally-induced 205–6. see also analgesia
PAIN (paracetamol, aspirin, ibuprofen, new tolerability) study 317–23
paracetamol
  adverse drug reactions 208, 248, 251, 316, 317
  anti-erythema activity 136
  cataract 213
  cataract prevention 213
  combination drugs for analgesia 350–1
  comparative studies 275
  fever/febrile states 262
  gastrointestinal effects 382, 400
  hepatic effects 434, 435, 438, 441
  osteoarthritis 239, 253, 264, 265–70, 272, 273
  PAIN study 317–23
  pharmacology 157, 165, 166, 174, 176
  rheumatic diseases 237–9, 253, 254, 256, 259–60, 275
  safety 314, 315
Parke Davis, USA, history 3
Parkinson’s disease 1, 559–61, 562
particle size-related physical characteristics 52
patent specifications 9, 51
Patient Activity Scale (PAS) 255
Pediatric Rheumatology Collaborative Study Group, US 261
Index

pharmaceuticals
management of ibuprofen overdose 515
PAIN study 318
pharmacokinetics of ibuprofen 86, 114–15, 247
renal effects 445
rheumatic diseases 116, 246, 261–2
toxicity 512–13
perinatal effects 479
peripheral nervous system (PNS) 145, 147
peritoneal adhesions 203–4
permeability, intestinal 364, 365, 381–9
pH, solubility of ibuprofen 53, 54
phagocytosis 188
Pharmaceutical Drug Classification system 50, 64
pharmaceutics of ibuprofen 72
physiochemical properties 50–4
in vitro/in vivo testing 58–60
worldwide production/products available 54, 55
see also formulations
pharmacist (P) supervised status 17, 18
pharmacology 132–4, 214
analgesia 143–9
animal models of analgesia 143–9
antipyretic activity 149
clinical 204–14, 239–47
conditional 432–3
experimental therapeutics 196–204
immune function 191
joint integrity 192–4
leukocyte inhibition/vascular permeability 182–91
leukotriene production 180–1
lipid metabolism 194–5
nitric oxide production 181–2
prostaglandins production 164–80
smooth muscle contractility 181
see also inflammation; toxicology
pharmokinetics (PK) 81, 84–8
absorption 82–3
clearance 92–105, 315
distribution 83–92
drug interactions 120–3
interspecific differences 105–6
rheumatic diseases 240–5, 277–8
special populations 108–20
therapeutic effects relative to plasma
concentration 106–7
toxokinetics 107–8, 502–8
phenacetin, history 5
phenoxy analogues 25
phenoxyalkanoic acids, history 10
phenoxypropionic acid 24
phenylacetic acids 25
phenylalkanoic acids 11, 23
phenylbutazone
allergy/hypersensitivity 455, 456
anti-arthritic effects 142
anti-erythema activity 136
gastrointestinal effects 151
history 5, 6, 7, 10
pharmacology 157, 165, 166
phenylpropionic acid 12, 25, 27, 31
phospholipids, and gastrointestinal effects 409–10
phthalates, history 10
physiochemical properties
and gastrointestinal effects 399–402
medicinal chemistry 42–3
pharmaceutics of ibuprofen 50–4
pirprofen, biological activity 34
PK, see pharmacokinetics
plant growth regulators, history 10
platelet aggregation 199–201, 206–8, 246, 390
drug interactions 484–5
epidemiological data 330
pleurisy 203
Poisons Information Centres 500
polymorphisms, clearance 94, see also genetics
polymorphonuclear (PMN) leukocytes 138, 186–8, 280–1
polymyxin B-induced paw oedema model 141
postoperative pain 281
postoperative pediatric patients 115
potency 14
analgesia 146–8, 147, 147
anti-inflammatory effects 137, 139, 141, 143
liquid preparations 261–2
see also comparative studies; dosage
PPIs (proton pump inhibitors) 239, 379, 398, 411
preclinical studies, cancer prevention/therapy 523–4
pregnancy 331–3, 513. see also reproductive effects
premature infants, pharmacokinetics 86, 115–16
premature labour, adverse drug reactions 479
prescription only (POM) status 1, 17, 18
presystemic chiral inversion 99–104
preventive analgesia, dentistry 348–9
primary osteoarthritis 262–76
probenecid, drug interactions 122
prodrugs, ibuprofen analogues 35
products available worldwide 51, 54, 55, 573–8
pro-inflammatory cytokines 132, 190–1
pharmacology/toxicology 138
primary and secondary osteoarthritis 262
surgical stress 203
see also interleukins; tumour necrosis factor-α
proline moieties 35
prostaglandins inhibition 81
anti-pyretic effects 149
cancer prevention/therapy 521
comparative studies 156–8, 159
enantiomers of ibuprofen 133
gastrointestinal effects 398
hepatorenal effects 433
history 2, 10
pharmacology/toxicology 132, 137, 138–9, 164–80
pregnancy 331
rheumatic diseases 241, 271
sports injuries 335
see also cyclooxygenase
prostanoids 172, 180, 196, 399–402
prostate cancer prevention/therapy 520, 521, 529–30, 532
proton pump inhibitors (PPIs) 239, 379, 398, 411
psychiatric effects 285, 481
pyrazolones 5, 6, 438
quantum mechanical studies 42–3
Québec Pregnancy Registry 331–2
Queen’s Award for Technological Achievement 19
R-ibuprofen 38–9, 50, 81
analysis 349–50
clearance 92, 93, 93–4
conversion to S-ibuprofen. see chiral inversion
cyclooxygenase inhibition 175, 179
distribution 91
elderly patients 285
enantiomer-enantiomer interactions 123
febrile children and infants 114–15
gastrointestinal effects 153, 248
interspecific differences 105–6
pharmacology/toxicology 133
pharmacokinetics 245
prostaglandins production 170–1
protein binding 83, 90
rheumatic diseases 240, 277–8
tissue distribution 89, 91
urinary excretion 105
see also racemic ibuprofen
rabbits 102, 105–6. see also animal models
race. see ethnic differences
racemic ibuprofen 50, 81
absorption 82
analgesia 112, 349–50
clearance 94
comparative ulcerogenicity 153
medicinal chemistry 31, 36, 37, 39, 40, 42
rheumatic diseases 277–8
most entries refer to this form, for exceptions see R-ibuprofen; S-ibuprofen
radiochromium Cr-labelled red blood cell technique 389–94
Randall–Selitto assay 10–11, 143
ranitidine, drug interactions 120–1
rats
acute anti-inflammatory effects 136–7
adjuvant arthritis 141–3
chiral inversion 97–8, 102, 104
comparative ulcerogenicity 150–3
compounds in development 25, 26
paw oedema test 10, 32, 136, 138–9, 140
pharmacokinetics of ibuprofen 105–6
Randall–Selitto assay 10–11, 143
see also animal models; rodent models
RB 1472 8
RD 8402 15
RD 10335 11, 15, 24, 25, 238
RD 13621 12–14, 17
RD 10499 11, 12, 15, 24, 25
RD 13621 12–14, 17
reactive arthritis 280
reactive oxygen species 132, 188–90, 334, 561
rectal suppositories 69, 82–3
Reiter’s syndrome 280
renal effects 133, 251, 442–6, 432–3, 446–70
cancer prevention/therapy 535
chronic use 513–14
elderly patients 285
epidemiological data 468–70
primary and secondary osteoarthritis 264
toxicology 163, 509–10
renal insufficiency 84, 118
reproductive effects
adverse drug reactions 477–80
obstetrics 211–12
teratogenic effects 164, 331–3, 477–9
toxicology 164, 513
respiratory effects 323, 512
response variability, rheumatic diseases 276–8
reversed-passive Arthus (RPA) reaction 141
rheumatic diseases 237–9, 286–7
adverse drug reactions 248–54
ankylosing spondylitis 280
clinical pharmacology 239–47
dexibuprofen 286
fibromyalgia 281
formulations 276
gastrointestinal effects 367
gout 280–1
haemophiliac arthritis 281
juvenile rheumatoid arthritis 261–2
low back pain 278–9
pharmacokinetics of ibuprofen 117–18
rheumatic diseases (cont’d)

primary and secondary osteoarthritis 262–76
psoriatic arthritis 280
reactive arthritis 280
response variability 276–8
rheumatoid arthritis 254–61
shoulder pain 279–80
see also below
rheumatic fever, history 6
rheumatoid arthritis 254–61
aspirin 23
history 2, 5, 6, 10–14
juvenile 261–2
renal effects 442
safety and effectiveness 332
sustained release technologies 62
risk factors
gastrointestinal effects 395, 395–9, 396
hepatic effects 437, 440
rodent models, Alzheimer’s disease 556–8. see also rats
rofecoxib 239, 251
adverse drug reactions 374
cardiovascular risk 252
gastrointestinal effects 250, 253, 382, 400, 401, 402
rheumatic diseases 275
Routine Assessment of Patient Index Data with three measures (RAPID-3) 255
RPA (reversed-passive Arthus) reaction 141
S–ibuprofen 31, 38–42, 50
absorption 82
analgesia 147, 349–50
clearance 92, 93, 93–4
comparative ulcerogenicity 153
conversion from R-ibuprofen. see chiral inversion
cyclooxygenase inhibition 135, 175, 179
distribution 91
elderly patients 285
enantiomer-enantiomer interactions 123
fast-acting preparations 66
febrile children and infants 114–15
interspecific differences 105–6
pharmacology/toxicology 133
pharmokinetics 245
prostaglandins inhibition 137
prostaglandins production 170–1
protein binding 83, 90
rheumatic diseases 240, 277–8
tissue distribution 89, 91
urinary excretion 105
see also dexibuprofen; racemic ibuprofen
safety 237–8, 313–15, 316, 317, 336, 412
animal models 135
cancer prevention/therapy 535–6
clinical trials 315–27
epidemiological data 327–30
history 14–15, 18
special populations 330–5
over-the-counter status 17–19, 500
rheumatic diseases 247
see also adverse drug reactions; overdose;
toxicology
St John’s Wort 86, 438, 440
salicylates 22
anti-erythema activity 136
drug-induced liver injuries 438
gastrointestinal effects 151
history 5, 10
pharmacology 157, 166, 176
see also aspirin
saliva, tissue distribution 91
Salmonella enteritidis 196–8
salts and derivatives of ibuprofen 82
dentistry 354–5
fast-acting preparations 64–6
gastrointestinal effects 404–6
Saren (ibuprofen lysinate) 64–5
Scotland 456–7
secondary osteoarthritis 262–76
Seractil (dexibuprofen) 39, 66, 270, 278, 286, 580. see also S–ibuprofen
serotonin, effect on gastric acidity 404
Shen, Dr T. Y. 3, 5
shoulder pain 279–80
side-effects. see adverse drug reactions
sigmoid Emax model, toxicity 107–8
significant gastrointestinal adverse event (SGAE)
PAIN study 321
Simplified Disease Activity Index (SDAI), rheumatoid arthritis 255
skin side-effects. see dermatological effects
sleep patterns 254
small bowel inflammation (enteropathy) 364, 365, 381–9
smoking, and gastrointestinal effects 395, 396
smooth muscle contractility 181
sodium carboxymethylcellulose 61
sodium ibuprofen hydrate 66
sodium salicylate, history 6
soldiers on active service 120
solid dosage form 54–66
solubility, ibuprofen 52–3, 53, 54, 82
soluble fast-acting preparations 64–6. see also effervescent formulations
special populations
  pharmokinetics of ibuprofen 108–20
  safety and effectiveness 330–5
  see also elderly patients; pediatrics
Spedifen (ibuprofen/arginine combination) 64
sports injuries 282–3, 334–5
St John’s Wort 86, 438, 440
Staphylococcus spp. 149, 191
stereoisomers, metabolites of ibuprofen 36–7
stress 120, 203
SUCCESS study, gastrointestinal effects 377
sucralfate, drug interactions 121
sulindac
  allergy/hypersensitivity 456
  anti-erythema activity 136
  gastrointestinal effects 370, 375, 400, 402
  hepatic effects 435
  history 5
  pharmacology 157, 166, 174, 176
  ‘super aspirin’ 6, 10, 17
super base, synthetic routes to ibuprofen 30, 31
suppositories 69, 82–3
suprofen
  pharmacology 174
  renal effects 470
surgical stress 203
sustained release technologies 60–3, 238
dentistry 354–5
gastrointestinal effects 403
rheumatic diseases 276
swallowing properties 50, 53, 62, 65, 67
symptom-based studies, gastrointestinal effects 378–9
synovial fluid concentrations 88–91, 242–3
synthesis, metabolites of ibuprofen 37–8
synthetic routes to ibuprofen, medicinal chemistry 27–31
systemic lupus erythematosus 254, 332, 440, 442
tablets, solid dosage form 56–8
TARGET study 276, 377, 412, 471
taste 50, 53, 62, 67
taste-masking 67–9
Tayside (Scotland), Medicines Monitoring Unit 368
temporomandibular disorders (TMD) 356–8
tensile strength (TS), tablet 56, 65
teratogenic effects 164, 331–3, 477–9
The Testing of Non-hormonal Anti-rheumatic Compounds (Adams) 5–6
Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) 276, 377, 412, 471
therapeutic index (TI) 133
therapeutic response
  pharmokinetics of ibuprofen 106–7
  rheumatic diseases 247
thermodynamic dissociation constant, physiochemical properties 43
3-α-hydroxysteroid dehydrogenase 195–6
thrombocytopenia 198, 253, 466, 504, 507, 512
thrombosis 199–201, 206–8
thromboxane 285
thrombus prevention, ibuprofen analogues 35
TMD (temporomandibular disorders) 356–8
toll-like receptors (TLRs) 255
topical formulations 70–2, 276, 399–402
tourniquet shock ischemia 202
toxic shock 191, 196–8
toxicology 149, 214
clinical 204–14, 239–47
conditional 432–3
experimental therapeutics 196–204
immune function 191
joint integrity 192–4
leukocyte inhibition/vascular permeability 182–91
lipid metabolism 194–5
pharmokinetics 107–8, 502–8
smooth muscle contractility 181
see also adverse drug reactions; overdosage; safety
Trafuryl erythema assay 7–8
transcutaneous hypoxia 202
triglycerides, pharmacology/toxicology 194–5
tri-layer tablets, taste-masking 69
tumour necrosis factor-α (TNF-α) 190–1
  pharmacology/toxicology 138
  primary and secondary osteoarthritis 262
  rheumatoid arthritis 255
2-4-(biphenylyl) propionic acid 23, 24
2-(4-substituted-phenyl) propionic acids 26
2-arylpropionic acids 31, 81
ulceration 150–3, 363, 364, 365–9. see also gastrointestinal effects
ulcerative proctitis 253
United Kingdom 460, 461, 462
United States 54, 55, 461, 464
Upjohn Company, USA 19
UV (ultraviolet) erythema assay 240
  acute anti-inflammatory effects 136–7
  biological activity of ibuprofen analogues 32, 33
  compounds in development 23, 24, 26
  history 3, 6, 7, 10, 15
  metabolites of ibuprofen 36
  synthetic routes to ibuprofen 27
uveitis 204
valproic acid, drug interactions 123
Vane, J. R. 2, 10
variability in response, chronic pain 276–8
vascular adhesion molecules (VCAM) 182, 183, 185
vascular permeability, pharmacology/toxicology 182–91
Verticillium lecanii 106
VIGOR study, gastrointestinal effects 376–8, 388
Visual Analogue Scale (VAS) 247
vomiting 316, 320, 323

warfarin, drug interactions 246, 253, 330, 445, 484–5
water solubility, physiochemical properties 42
weakness (asthenia) 320
Western Ontario and McMaster universities (WOMAC) criteria, therapeutic response 247
Wilhelmi, G. 3

Winder, Dr Steve 3
worldwide developments 19
worldwide production/products available 51, 54, 55, 573–8
wound repair inhibition 285
xanthan gum formulations, sustained release 62
X-ray studies, enantiomers of ibuprofen 39–40

yeast-induced fever test 149, 240
zaleplon, drug interactions 123
zidovudine, drug interactions 121
zomepirac
allergy/hypersensitivity 456
hepatic toxicity 436
pharmacology 174